Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

Approximately two-thirds of the world's population under the age of 50 years have oral or genital herpes simplex type 1 (HSV-1) infection, while one in eight have herpes simplex type 2 (HSV-2) ...

For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to replicate.

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

Even though genital herpes is fairly common (roughly one in six Americans has it, according to the Centers for Disease Control & Prevention [CDC]), it's highly stigmatized, in large part because ...

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. In the ...

BALA CYNWYD, PA, USA, September 15, 2023/EINPresswire.com/ -- A new advocacy effort is driving change as patients living with herpes globally are rallying for a cure ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...

Theralase® validates previous University of Manitoba research by demonstrating that Ruvidar TM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. Herpes Simplex ...